Send me a link:

*Only U.S. numbers are accepted. Text messaging rates may apply.

 Dow Up1.00% Nasdaq Up1.29%

Aeterna Zentaris Inc. (AEZS)

-NasdaqCM
1.12 0.05(4.67%) Apr 16, 3:59PM EDT
Get the big picture on all your investments.
ProfileGet Profile for:
Aeterna Zentaris Inc.
1405 du Parc-Technologique Boulevard
Quebec City, QC G1P 4P5
Canada - Map
Phone: 418-652-8525
Fax: 418-948-9191
Website: http://www.aezsinc.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:N/A

Business Summary 

Aeterna Zentaris Inc., a specialty biopharmaceutical company, develops and commercializes novel treatments in oncology and endocrinology worldwide. The company’s product pipeline includes MACRILEN, a product candidate for which the company has filed a New Drug Application to the FDA as an oral product used for evaluating adult growth hormone deficiency; and is also investigated in Phase 2A clinical trials to treat cancer-induced cachexia. Its product pipeline also comprises Zoptarelin doxorubicin, which has completed Phase 2 clinical trials to treat ovarian and endometrial cancer, and breast cancer; and Phase 1/2 clinical trials to treat bladder and prostate cancers. In addition, the company’s product candidates in clinical and preclinical development consist of AEZS-120, a live recombinant oral tumor vaccine candidate; PI3K/Erk inhibitors, including AEZS-129 and AEZS-136 for oncology; and disorazol Z product candidates, such as AEZS-137 and AEZS-125 for oncology. Aeterna Zentaris Inc. was founded in 1990 and is headquartered in Quebec City, Canada.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Aeterna Zentaris Inc.

Key Executives 
 PayExercised
Mr. Juergen Ernst M.B.A.,
Exec. Chairman and Member of Nominating, Governance & Compensation Committee
N/AN/A
Mr. David Alan Dodd , 64
Chief Exec. Officer, Pres and Director
390.00K0.00
Mr. Dennis Turpin CPA, CA,
Chief Financial Officer and Sr. VP
403.00K0.00
Mr. Jude Dinges ,
Chief Commercial Officer and Sr. VP
124.00K0.00
Dr. Richard Sachse M.D., Ph.D.,
Chief Scientific Officer, Chief Medical Officer and Sr. VP
N/AN/A
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.